Avadel Pharmaceuticals stock | Growth outlook for 2026 & price target

Avadel Pharmaceutica...

NasdaqGM:AVDL

$ 21,64

$0,00 (0,00%)

21,64 $

$0,00 (0,00%)

End-of-day quote: 02/13/2026

Avadel Pharmaceuticals Stock Value

The current analyst rating for NasdaqGM:AVDL is sf_Data Unavailable.

Avadel Pharmaceuticals Company Info

EPS Growth 5Y

5,59%

Market Cap

$2,12 B

Long-Term Debt

$0,04 B

Annual earnings

N/A

Dividend

$0,00

Dividend Yield

0,00%

Founded

2015

Industry

Health Care

Country

Ireland

Website

Avadel Pharmaceuticals

ISIN Number

IE00BDGMC594

Website

http://www.avadel.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

There are currently no price targets available for this stock.

In the last five quarters, Avadel Pharmaceuticals’s Price Target has risen from $18,40 to $18,40 - a 0,00% increase. Seven analysts predict that Avadel Pharmaceuticals’s share price will fall in the coming year, reaching $0,00. This would represent a decrease of -100,00%.

Top growth stocks in the health care sector (5Y.)

What does Avadel Pharmaceuticals do?

Avadel Pharmaceuticals plc (Avadel) operates as a biopharmaceutical company. LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. As of December 2024, LUMRYZ is the only commercial product in the company’s portfolio. LUMRYZ LUMRYZ was approved by the U.S. Food and Drug Administration (FDA) on May 1, 2023, for the treatment of cataplexy or EDS in adults w...

Avadel Pharmaceuticals plc (Avadel) operates as a biopharmaceutical company.

LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. As of December 2024, LUMRYZ is the only commercial product in the company’s portfolio.

LUMRYZ

LUMRYZ was approved by the U.S. Food and Drug Administration (FDA) on May 1, 2023, for the treatment of cataplexy or EDS in adults with narcolepsy. The FDA also granted seven years of Orphan Drug Exclusivity (‘ODE’) to LUMRYZ for the treatment of cataplexy or EDS in adults with narcolepsy due to a finding of clinical superiority of LUMRYZ relative to marketed oxybate treatments. In particular, the FDA found that LUMRYZ makes a major contribution to patient care over marketed, twice-nightly oxybate treatments by providing a once-nightly dosing regimen that avoids nocturnal arousal to take a second dose. In June 2023, the company announced the U.S. commercial launch of LUMRYZ for the treatment of cataplexy or EDS in adults living with narcolepsy. LUMRYZ was approved by the FDA for use in the treatment of cataplexy or EDS in the pediatric narcolepsy population seven years of age and older on October 16, 2024, and was granted ODE for this patient population through October 16, 2031.

Under the LUMRYZ REMS, healthcare providers who prescribe the drug must be specially certified, pharmacies that dispense the drug must be specially certified, and the drug must be dispensed only to patients who have enrolled in the LUMRYZ REMS and completed all Risk Evaluation and Mitigation Strategy (REMS) requirements, including documentation of safe use conditions.

The company has 30 U.S. patents listed for LUMRYZ in FDA’s Orange Book. With respect to clinical data generated for LUMRYZ, it conducted a Phase 3 clinical trial of LUMRYZ (the ‘REST-ON trial’), which was a randomized, double-blind, placebo-controlled study that enrolled patients who received at least one dose of LUMRYZ or placebo, and was conducted in clinical sites in the U.S., Canada, Western Europe and Australia.

Additionally, the company’s open-label extension/switch study of LUMRYZ (‘RESTORE’) examined the long-term safety and maintenance of efficacy of LUMRYZ in patients with narcolepsy who participated in the REST-ON trial, as well as dosing and preference data for patients who switched from twice-nightly sodium oxybate to once-at-bedtime LUMRYZ, regardless of whether they participated in the REST-ON trial.

Avadel has initiated a pivotal trial in IH, REVITALYZ, which is a double-blind, placebo-controlled, randomized withdrawal, multicenter Phase 3 study designed to evaluate the efficacy and safety of LUMRYZ, in treating IH.

Drug Delivery Technologies

The company owns drug delivery technologies that address formulation challenges, potentially allowing the development of differentiated drug products for administration in various forms (e.g., capsules, tablets, powders or liquid for oral use; or injectables for subcutaneous administration) that could be applied to a broad range of drugs.

A brief discussion of each of the company’s drug delivery technologies is set forth below.

MICROPUMP

The company’s MICROPUMP technology allows for the development of modified release solid, oral dosage formulations of drugs. A version of the company’s MICROPUMP technology is being employed in LUMRYZ.

LIQUITIME

The company’s LIQUITIME technology allows for the development of modified release oral products in a liquid suspension formulation.

MEDUSA

The company’s MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs (e.g., peptides, polypeptides, proteins, and small molecules).

Intellectual Property

Numerous LUMRYZ-related U.S. patents have been issued having expiration dates spanning from mid-2037 to early-2042, and there are additional patent applications in development and/or pending at the USPTO, as well as foreign patent offices.

Government Regulation

LUMRYZ is subject to regulation by the U.S. Drug Enforcement Administration (“DEA”) under the Controlled Substances Act (“CSA”), and its manufacturing and distribution are highly restricted.

The API in LUMRYZ, sodium oxybate, is a Schedule I controlled substance in the U.S., and the FDA-approved LUMRYZ product is a Schedule III controlled substance in the U.S.

In addition, the third parties who perform the company’s clinical and commercial manufacturing, distribution, dispensing and clinical studies for LUMRYZ are required to maintain necessary the U.S. Drug Enforcement Administration (DEA) registrations and state licenses.

History

The company was incorporated in 2015. It was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in 2017.

Avadel Pharmaceuticals Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Pharmaceutical Sales:** 100% (2026) **Top 3 Markets:** 1. **USA:** 75% 2. **Europe:** 15% 3. **Asia-Pacific:** 10% Avadel Pharmaceuticals plc generates its sales entirely from the pharmaceutical industry, with a focus on the development and marketing of medications. The largest market for the co...

At which locations are the company’s products manufactured?

**Production Sites:** USA and Ireland (estimated, 2023) Avadel Pharmaceuticals plc is a specialty pharmaceutical company that focuses on the development and commercialization of medications for the treatment of sleep disorders. Historically, the company has utilized production facilities in the USA...

What strategy does Avadel Pharmaceuticals pursue for future growth?

**Strategic Focus Points:** - **Product Development:** Focus on innovative therapies - **Market Expansion:** Accessing new geographical markets - **Partnerships:** Collaboration with other pharmaceutical companies Avadel Pharmaceuticals plc focuses on the development and marketing of innovative the...

Which raw materials are imported and from which countries?

**Main raw materials:** Sodium oxybate, pharmaceutical excipients **Countries of origin:** USA, Europe Avadel Pharmaceuticals plc is a company specializing in the development and marketing of medications, particularly in the field of sleep medicine. The main active ingredient in their leading pro...

How strong is the company’s competitive advantage?

**Market Share:** Estimated at 5-10% in the field of narcolepsy treatments (2026) **Research & Development:** 20% of revenue invested (2025) **Patent Portfolio:** Strong position secured with multiple patents until 2030 Avadel Pharmaceuticals plc has gained a significant competitive advan...

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Share:** 75% (estimated for 2026 based on historical trends) **Insider Purchases/Sales:** No specific data available for 2026 The institutional investor share in Avadel Pharmaceuticals plc is estimated to be around 75%. This is based on historical data and the typical beha...

What percentage market share does Avadel Pharmaceuticals have?

**Market share of Avadel Pharmaceuticals plc:** Estimated 5% (2026) **Main competitors and their market shares:** 1. Jazz Pharmaceuticals plc - 30% 2. Harmony Biosciences Holdings, Inc. - 20% 3. Takeda Pharmaceutical Company Limited - 15% 4. Axsome Therapeutics, Inc. - 10% 5. Avadel Pharmaceuticals...

Is Avadel Pharmaceuticals stock currently a good investment?

**Revenue Growth:** 18% (2025) **R&D Expenses:** 24% of revenue (2025) **Market Share in Main Segment:** 12% (2025) Avadel Pharmaceuticals plc recorded a revenue growth of 18% in 2025, attributed to successful product launches and increased market penetration. The company is heavily investing i...

Does Avadel Pharmaceuticals pay a dividend – and how reliable is the payout?

**Dividend payment:** None (as of 2026) Avadel Pharmaceuticals plc has not paid any dividends to its shareholders in the past. The company primarily focuses on research and development in the field of pharmaceuticals, which typically involves high investment costs. Pharmaceutical companies in a gr...

New support ticket

Explore

Avadel Pharmaceuticals Stock Value

Avadel Pharmaceuticals Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Avadel Pharmaceuticals do?

Avadel Pharmaceuticals Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Avadel Pharmaceuticals Stock Value

Avadel Pharmaceuticals Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Avadel Pharmaceuticals do?

Avadel Pharmaceuticals Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.